| Gene Symbol | OCLN |
| Full Name | Occludin |
| Chromosome | 5q13.2 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. ... |
| Mechanism of Action | Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. Therapeutic approaches would involve either direct protein stabilization or indirect modulation of occludin phosphorylation and trafficking to maintain barrier function. |
| Primary Expression | Brain endothelial cells, Epithelial tight junctions |
| Druggability | Low (0.32) |
| Clinical Stage | Approved |
| Molecular Weight | 65 kDa |
| Amino Acids | 522 aa |
| Pathways | Autophagy, Blood-Brain Barrier, Circadian Rhythm, Immune Response, Innate Immunity |
| UniProt ID | Q16625 |
| NCBI Gene ID | 4950 |
| Ensembl ID | ENSG00000130940 |
| OMIM | 602876 |
| GeneCards | OCLN |
| Human Protein Atlas | OCLN |
| Associated Diseases | Aging, Als, Alzheimer, anxiety |
| Known Drugs/Compounds | BENVITIMOD, BYF |
| Interactions | ABCB1, ABCG2, ACHE, ACTB, Actin, Adiponectin |
| SciDEX Target | View Target Profile (10 clinical trials) |
| KG Connections | 842 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!